Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MAZE Maze Therapeutics

Trading 08-05 12:35:28 EDT

28.06

+0.45

+1.61%

High28.93	Low27.67	Vol87.32K
Open27.93	D1 Closing27.61	Amplitude4.56%
Mkt Cap1.55B	Tradable Cap1.24B	Total Shares55.25M
T/O2.47M	T/O Rate0.20%	Tradable Shares44.26M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":28.055,"timestamp":1785947722819,"preClose":27.61,"halted":0,"volume":87323,"delay":0,"changeRate":0.016117348786671506,"floatShares":44261020,"shares":55248700,"eps":-2.48598,"marketStatus":"Trading","change":0.445,"latestTime":"08-05 12:35:28 EDT","open":27.93,"high":28.93,"low":27.67,"amount":2473051.280436,"amplitude":0.045636,"askPrice":28.14,"askSize":223,"bidPrice":28.02,"bidSize":112,"shortable":3,"etf":0,"ttmEps":-2.48598,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1785960000000},"marketStatusCode":2,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":27.61,"postHourTrading":{"tag":"盘后","latestPrice":27.61,"preClose":27.61,"latestTime":"19:34 EDT","volume":10338,"amount":285432.63,"timestamp":1785886441361,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.550667,"impliedVol":0.7133,"impliedVolPercentile":0.5766},"requestUrl":"/m/hq/s/MAZE/tweets","defaultTab":"tweets","newsList":[{"id":"2656399196","title":"Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $204,859.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399196","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399196?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:16","pubTimestamp":1785528987,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares worth $204,859.44Maze Therapeutics CSBO Atul Dandekar exercised options for 7,500 shares at USD 10.42 on July 29, 2026.He sold 7,50","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL2jSdyV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Disposes of 7,500 Common Shares Worth $204,859.44","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652284332","title":"Maze Therapeutics (MAZE) Stock Looks Fully Priced After A 59% Gain##","url":"https://stock-news.laohu8.com/highlight/detail?id=2652284332","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652284332?lang=en_us&edition=fundamental","pubTime":"2026-07-17 22:20","pubTimestamp":1784298025,"startTime":"0","endTime":"0","summary":"Maze Therapeutics stock has delivered a strong 59.2% return over the past year, yet its low value score and an overvalued read on market multiples suggest investors are paying up without a clear margin of safety.\n\nOver the last 12 months, Maze Therapeutics has returned 59.2%, which puts the spotlight on whether recent gains already reflect much of the good news investors expect.\nFuture progress in turning its pipeline into consistent, scalable cash flows can support the current share price,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-maze/maze-therapeutics/news/maze-therapeutics-maze-stock-looks-fully-priced-after-a-59-g","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-maze/maze-therapeutics/news/maze-therapeutics-maze-stock-looks-fully-priced-after-a-59-g","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MAZE","BK4007","TSPA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651488864","title":"Maze Therapeutics Advances MZE782 Phase 2 PKU Trial, Setting Up a New Catalyst for MAZE Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2651488864","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651488864?lang=en_us&edition=fundamental","pubTime":"2026-07-15 00:31","pubTimestamp":1784046697,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. ($MAZE) announced an update on their ongoing clinical study. The Phase 2 study “A Phase 2, Randomized, Double-blind, Placeb...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-advances-mze782-phase-2-pku-trial-setting-up-a-new-catalyst-for-maze-investors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-advances-mze782-phase-2-pku-trial-setting-up-a-new-catalyst-for-maze-investors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ISBC","MAZE","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648863335","title":"Maze Therapeutics CEO Jason V. Coloma Disposes of 34,501 Common Shares Worth $1.03 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2648863335","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648863335?lang=en_us&edition=fundamental","pubTime":"2026-07-03 04:29","pubTimestamp":1783024191,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CEO Jason V. Coloma disposes of 34,501 common shares worth $1.03 millionMaze Therapeutics CEO Jason V. Coloma sold 34,501 shares of common stock on July 1.Sales prices averaged about","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260702:nNDL42GkCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CEO Jason V. Coloma Disposes of 34,501 Common Shares Worth $1.03 Million","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648526615","title":"Maze Therapeutics CSBO Atul Dandekar Disposes of $210,150 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2648526615","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648526615?lang=en_us&edition=fundamental","pubTime":"2026-07-02 04:18","pubTimestamp":1782937087,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar disposes of $210,150 in common sharesMaze Therapeutics CSBO Atul Dandekar exercised stock options for 7,500 shares at USD 10.42 on June 29, 2026.Dandekar sold 7,50","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDL3bsslX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CSBO Atul Dandekar Disposes of $210,150 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646459568","title":"Maze Therapeutics CEO Jason V. Coloma Sells USD 723,021 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2646459568","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646459568?lang=en_us&edition=fundamental","pubTime":"2026-06-25 04:15","pubTimestamp":1782332157,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CEO Jason V. Coloma sells USD 723,021 in common sharesMaze Therapeutics CEO Jason V. Coloma reported sales of 27,858 common shares on June 22-23.Shares sold at weighted average price","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260624:nNDL4PsQVf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CEO Jason V. Coloma Sells USD 723,021 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029997","title":"Analysts Offer Insights on Healthcare Companies: Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and Universal Health (UHS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029997","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029997?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:46","pubTimestamp":1782125207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zymeworks (ZYME), Maze Therapeutics, Inc. (MAZE) and...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-maze-therapeutics-inc-maze-and-universal-health-uhs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-zymeworks-zyme-maze-therapeutics-inc-maze-and-universal-health-uhs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4185","BK4139","LU0029874061.USD","LU0128526141.USD","HCSG","BK4588","ZYME","UHS","XBI","BK4581","MAZE","XLV","LABU","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642627471","title":"Maze Therapeutics Shareholders Elect Directors, Ratify Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2642627471","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642627471?lang=en_us&edition=fundamental","pubTime":"2026-06-11 06:07","pubTimestamp":1781129256,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Maze Therapeutics, Inc. ( ($MAZE) ). On June 8, 2026, Maze Therapeutics, Inc. held its 2026 annual meeting of s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-shareholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-shareholders-elect-directors-ratify-auditor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642734475","title":"Maze Therapeutics shareholders elect Coloma, Kumar as directors at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2642734475","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642734475?lang=en_us&edition=fundamental","pubTime":"2026-06-11 04:16","pubTimestamp":1781122595,"startTime":"0","endTime":"0","summary":"Maze Therapeutics held its annual shareholder meeting on June 8, 2026.Stockholders chose Jason Coloma and Neil Kumar to serve as Class I directors through the 2029 annual meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260610:nNDL6WVkM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640918476","title":"Maze Therapeutics CEO Jason V. Coloma sells 6,643 shares worth $174,171.83","url":"https://stock-news.laohu8.com/highlight/detail?id=2640918476","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640918476?lang=en_us&edition=fundamental","pubTime":"2026-06-04 05:04","pubTimestamp":1780520689,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CEO Jason V. Coloma sold 6,643 shares of common stock on June 1.Shares sold at weighted average prices of $26.2 and $26.24.Holdings fell to 344,897 shares in the Coloma Family Trust; 27,970 shares in The Coloma 2021 Irrevocable Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL9YjWt6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CEO Jason V. Coloma sells 6,643 shares worth $174,171.83","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640118420","title":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of common shares worth $381,499.47","url":"https://stock-news.laohu8.com/highlight/detail?id=2640118420","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640118420?lang=en_us&edition=fundamental","pubTime":"2026-06-04 05:02","pubTimestamp":1780520539,"startTime":"0","endTime":"0","summary":"Sales priced at USD 25.57 and USD 26.36; holdings fell to zero shares.He exercised stock options for 14,853 shares at USD 10.42 in the same session.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDLcbqklh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of common shares worth $381,499.47","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640906737","title":"Maze Therapeutics posts corporate presentation on genetics-driven kidney, metabolic disease drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2640906737","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640906737?lang=en_us&edition=fundamental","pubTime":"2026-06-03 19:10","pubTimestamp":1780485039,"startTime":"0","endTime":"0","summary":"Maze Therapeutics outlined a kidney and metabolic disease pipeline, led by MZE829, a selective APOL1 inhibitor for APOL1-mediated kidney disease.Phase 2 HORIZON initial data showed a 36% mean uACR reduction across 12 evaluable patients; 50% achieved at least a 30% reduction.Non-diabetic patients showed a 49% mean uACR reduction; the FSGS subset showed a 62% mean reduction, supporting plans for a pivotal program.Additional HORIZON data targeted for late 2026 or early 2027; pivotal trial initiation targeted for 1H 2027, subject to regulatory feedback.Cash runway expected into 2029 under the current business plan.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this new","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL8W3B5w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640230549","title":"Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares for $197,554‬","url":"https://stock-news.laohu8.com/highlight/detail?id=2640230549","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640230549?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:12","pubTimestamp":1780431176,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CSBO Atul Dandekar sold 7,500 common shares on May 29 at USD 26.34.The sale followed the exercise of 7,500 stock options at USD 10.42.Dandekar ended the day with 24,808 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260602:nNDLNYsKv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Maze Therapeutics CSBO Atul Dandekar disposes of 7,500 common shares for $197,554‬","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638357086","title":"Maze Therapeutics CEO Jason V. Coloma disposes of 32,564 common shares worth $846,980.45","url":"https://stock-news.laohu8.com/highlight/detail?id=2638357086","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638357086?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:17","pubTimestamp":1779913063,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CEO Jason V. Coloma disclosed sales of 32,564 common shares at about USD 26 per share on May 22 and May 26.The shares were sold from trusts in which Coloma reports indirect beneficial ownership.Holdings reported after the sales were 350,987 shares in the Coloma Family Trust and 28,523 shares in The Coloma 2021 Irrevocable Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL9Qv1F0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics CEO Jason V. Coloma disposes of 32,564 common shares worth $846,980.45","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638049545","title":"Maze Therapeutics to Participate in Two Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2638049545","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638049545?lang=en_us&edition=fundamental","pubTime":"2026-05-27 19:03","pubTimestamp":1779879780,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., May  27, 2026  (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for pat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/27/3301796/0/en/Maze-Therapeutics-to-Participate-in-Two-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637032299","title":"J.P. Morgan Keeps Their Buy Rating on Maze Therapeutics, Inc. (MAZE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2637032299","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637032299?lang=en_us&edition=fundamental","pubTime":"2026-05-23 20:15","pubTimestamp":1779538559,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Anupam Rama maintained a Buy rating on Maze Therapeutics, Inc. yesterday and set a price target of $53.00. The company’s shares...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-buy-rating-on-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-keeps-their-buy-rating-on-maze-therapeutics-inc-maze-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637834057","title":"Maze Therapeutics CFO Expands Role Amid Finance Leadership Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2637834057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637834057?lang=en_us&edition=fundamental","pubTime":"2026-05-23 07:27","pubTimestamp":1779492423,"startTime":"0","endTime":"0","summary":"Maze Therapeutics, Inc. ( ($MAZE) ) just unveiled an announcement. On May 18, 2026, Maze Therapeutics, Inc. announced that Senior Vice President of...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-cfo-expands-role-amid-finance-leadership-change?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/maze-therapeutics-cfo-expands-role-amid-finance-leadership-change?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637342172","title":"Maze Therapeutics SVP Finance Amy Bachrodt resigns, effective June 1","url":"https://stock-news.laohu8.com/highlight/detail?id=2637342172","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637342172?lang=en_us&edition=fundamental","pubTime":"2026-05-23 05:25","pubTimestamp":1779485119,"startTime":"0","endTime":"0","summary":"The departure was not tied to any disagreement over operations, policies, practices, or financial reporting.CFO Misbah Tahir will take on the principal accounting officer role following Bachrodt’s exit.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL1frN5q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636001678","title":"Maze CEO Jason Coloma disposes 1,938 Maze Therapeutics shares worth $50,388","url":"https://stock-news.laohu8.com/highlight/detail?id=2636001678","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636001678?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:08","pubTimestamp":1779138488,"startTime":"0","endTime":"0","summary":"Maze Therapeutics CEO Jason V. Coloma sold 1,938 shares of common stock on May 15 at USD 26 per share.The sales were reported as indirect holdings through the Coloma Family Trust and The Coloma 2021 Irrevocable Trust.Indirect holdings following the transactions were 381,073 shares in the family trust, 31,001 shares in the irrevocable trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLb2zWdh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MAZE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636001682","title":"Maze Therapeutics President R&D, CMO Harold Bernstein sells common shares worth $393,354","url":"https://stock-news.laohu8.com/highlight/detail?id=2636001682","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636001682?lang=en_us&edition=fundamental","pubTime":"2026-05-19 05:04","pubTimestamp":1779138261,"startTime":"0","endTime":"0","summary":"Maze Therapeutics President, R&D and CMO Harold Bernstein exercised stock options for 15,000 shares at USD 10.42 on May 14.Bernstein sold 15,000 shares the same day at a weighted average price of USD 26.22, leaving him with no directly held common stock.He reported beneficial ownership of 222,407 stock options following the transactions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL3XFz4H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Maze Therapeutics President R&D, CMO Harold Bernstein sells common shares worth $393,354","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.mazetx.com;ir.mazetx.com","stockEarnings":[{"period":"1week","weight":-0.0097},{"period":"1month","weight":-0.1168},{"period":"3month","weight":0.0431},{"period":"6month","weight":-0.3718},{"period":"1year","weight":0.8105},{"period":"ytd","weight":-0.3336}],"compareEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":0.0356},{"period":"3month","weight":0.0511},{"period":"6month","weight":0.1383},{"period":"1year","weight":0.2221},{"period":"ytd","weight":0.1311}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"NASDAQ","name":"Maze Therapeutics","nameEN":"Maze Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Maze Therapeutics,MAZE,Maze Therapeutics股票,Maze Therapeutics股票老虎,Maze Therapeutics股票老虎国际,Maze Therapeutics行情,Maze Therapeutics股票行情,Maze Therapeutics股价,Maze Therapeutics股市,Maze Therapeutics股票价格,Maze Therapeutics股票交易,Maze Therapeutics股票购买,Maze Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Maze Therapeutics(MAZE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Maze Therapeutics(MAZE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction